Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints

Innate Pharma SA IPHA has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia did not meet its primary endpoints in all three cohorts trial.
Based on these results, the Company will stop exploring avdoralimab in COVID-19.
The trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit activation of the C5a/C5aR1 pathway.
These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care.
Investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without establishing any causality.
Results from this trial, including translational data, are planned to be submitted for publication.
Price Action: IPHA shares closed at $3.52 on Friday.